Pharmacokinetic considerations for treatment of bacterial peritonitis during continuous ambulatory peritoneal dialysis.
Bouchet
J L
JL
CTMR Saint-Augustin, Department of Nephrology, Hôpital Pellegrin, Bordeaux, France.
Aparicio
M
M
Vinçon
G
G
Demotes-Mainard
F
F
Quentin
C
C
Bourdenx
J P
JP
Dupoux
J
J
Potaux
L
L
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005578:Fosfomycin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009070:Moxalactam / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010538:Peritonitis / Q000188:drug therapy*
D005578:Fosfomycin; D002439:Cefotaxime; D009070:Moxalactam